MedTrace Logo

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

NCT06776432 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-06

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.

Conditions

Interventions

DRUG

Sivopixant

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm.

DRUG

Acetazolamide

Administered as specified in the treatment arm

DRUG

SASS-001

Administered as specified in the treatment arm

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Principal Investigators

  • Chief Scientific Officer · Apnimed

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-02
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06776432 on ClinicalTrials.gov